Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives $181.43 Average PT from Brokerages

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $181.4286.

Several equities research analysts recently commented on JAZZ shares. Piper Sandler reiterated an “overweight” rating and issued a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Zacks Research upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Wall Street Zen downgraded Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 15th. Royal Bank Of Canada reduced their price objective on Jazz Pharmaceuticals from $182.00 to $172.00 and set an “outperform” rating for the company in a report on Wednesday, May 7th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Jazz Pharmaceuticals in a report on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price objective for the company.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the sale, the chief executive officer directly owned 436,973 shares in the company, valued at approximately $47,031,403.99. This trade represents a 0.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Teacher Retirement System of Texas lifted its position in shares of Jazz Pharmaceuticals by 0.6% during the 2nd quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company’s stock valued at $1,651,000 after buying an additional 90 shares in the last quarter. Versant Capital Management Inc lifted its position in shares of Jazz Pharmaceuticals by 9.4% during the 1st quarter. Versant Capital Management Inc now owns 1,058 shares of the specialty pharmaceutical company’s stock valued at $131,000 after buying an additional 91 shares in the last quarter. Kendall Capital Management lifted its holdings in Jazz Pharmaceuticals by 1.2% in the 1st quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company’s stock worth $989,000 after purchasing an additional 95 shares in the last quarter. Quarry LP lifted its holdings in Jazz Pharmaceuticals by 6.3% in the 4th quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $209,000 after purchasing an additional 100 shares in the last quarter. Finally, Louisiana State Employees Retirement System lifted its holdings in Jazz Pharmaceuticals by 0.6% in the 1st quarter. Louisiana State Employees Retirement System now owns 16,900 shares of the specialty pharmaceutical company’s stock worth $2,098,000 after purchasing an additional 100 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $119.07 on Friday. Jazz Pharmaceuticals has a 1-year low of $95.49 and a 1-year high of $148.06. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The business has a fifty day moving average price of $112.24 and a 200-day moving average price of $117.15. The company has a market capitalization of $7.22 billion, a PE ratio of -17.69, a PEG ratio of 7.51 and a beta of 0.34.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the previous year, the business earned $5.30 earnings per share. Jazz Pharmaceuticals’s revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, equities analysts expect that Jazz Pharmaceuticals will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.